Predictive Factors in OCT Analysis for Visual Outcome in Exudative AMD

Background. Reliable predictive factors for therapy outcome may enable treating physicians to counsel their patients more efficiently concerning probability of improvement or time point of discontinuation of a certain therapy.Methods. This is a retrospective analysis of 87 patients with exudative age-related macular degeneration who received three monthly intravitreal ranibizumab injections. Visual acuity before initiation of intravitreal therapy and 4–6 weeks after last intravitreal injection was compared and related to the preoperative visualisation of continuity of the outer retinal layers as assessed by OCT: external limiting membrane (ELM), inner photoreceptor segments (IPS), junction between inner and outer segments (IS/OS), and outer photoreceptor segments (OPS).Results. Visual acuity increased in 40 of 87 (46.0%) patients, it remained stable in 25 (28.7%), and 22 (25.3%) patients had decreased visual acuity four to six weeks after triple intravitreal ranibizumab injections. No statistically significant predictive value could be demonstrated for grade of continuity of outer retinal layers concerning visual acuity development.Conclusions. In our series of AMD patients, grade of continuity of outer retinal layers was not a significant predictive value for visual acuity development after triple ranibizumab injections.

Download Full-text

Intravitreal ranibizumab for neovascular age-related macular degeneration patients with good baseline visual acuity and the predictive factors for visual outcomes

Journal Français d Ophtalmologie ◽

10.1016/j.jfo.2013.08.006 ◽

2014 ◽

Vol 37 (4) ◽

pp. 280-287 ◽

Cited By ~ 3

Author(s):

A. Ozkaya ◽

Z. Alkin ◽

O.A. Osmanbasoglu ◽

H.M. Ozkaya ◽

A. Demirok

Keyword(s):

Visual Acuity ◽

Macular Degeneration ◽

Predictive Factors ◽

Age Related Macular Degeneration ◽

Intravitreal Ranibizumab ◽

Visual Outcomes ◽

Age Related ◽

Baseline Visual Acuity

Download Full-text

CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE

Retina ◽

10.1097/iae.0000000000000548 ◽

2015 ◽

Vol 35 (9) ◽

pp. 1743-1749 ◽

Cited By ~ 33

Author(s):

Eric H. Souied ◽

Hassiba Oubraham ◽

Gérard Mimoun ◽

Salomon Y. Cohen ◽

Stéphane Quere ◽

...

Keyword(s):

Visual Acuity ◽

Clinical Practice ◽

Macular Degeneration ◽

Daily Clinical Practice ◽

Age Related Macular Degeneration ◽

Intravitreal Ranibizumab ◽

Age Related

Download Full-text

Three-Year Visual Outcome and Injection Frequency of Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

Ophthalmologica ◽

10.1159/000350238 ◽

2013 ◽

Vol 230 (1) ◽

pp. 27-33 ◽

Cited By ~ 5

Author(s):

Ramu Muniraju ◽

Jayashree Ramu ◽

Sobha Sivaprasad

Keyword(s):

Macular Degeneration ◽

Visual Outcome ◽

Age Related Macular Degeneration ◽

Intravitreal Ranibizumab ◽

Age Related ◽

Injection Frequency

Download Full-text

Morphologic Changes in Patient with Drusen and Drusenoid Pigment Epithelial Detachment after Intravitreal Ranibizumab for Choroidal Neovascular Membrane : A Case Report

The Open Ophthalmology Journal ◽

10.2174/1874364101610010001 ◽

2016 ◽

Vol 10 (1) ◽

pp. 1-4 ◽

Cited By ~ 2

Author(s):

Sukjin Kim ◽

Jeongjae Oh ◽

Kiseok Kim

Keyword(s):

Visual Acuity ◽

Case Report ◽

Age Related Macular Degeneration ◽

Pigment Epithelial Detachment ◽

Choroidal Neovascular Membrane ◽

Intravitreal Ranibizumab ◽

Pigment Epithelial ◽

Age Related ◽

The Right ◽

Morphologic Changes

The authors present a case of morphologic changes of drusen and drusenoid pigment epithelial detachment (DPED) after treating choroidal neovascularization (CNV) using ranibizumab in age-related macular degeneration (AMD). A 71-year-old woman has noticed mild visual acuity deterioration in the right eye for several months. She was presented with some drusen and DPED associated with CNV. This patient was given intravitreal injection of 0.5 mg of ranibizumab five times at monthly intervals for treating CNV. DPED in the temporal and drusen in the superior to macula were diminished, which continued up to 2 months. Intravitreal ranibizumab injection may have influenced with diminishment of drusen and DPED. After 2 months, CNV was recurred.

Download Full-text

Limited Treatment Response during Follow-up after Switching to Aflibercept in Neovascular Age-related Macular Degeneration

Journal of the Korean Ophthalmological Society ◽

10.3341/jkos.2021.62.9.1218 ◽

2021 ◽

Vol 62 (9) ◽

pp. 1218-1226

Author(s):

Gon Soo Choe ◽

Jong Woo Kim ◽

Chul Gu Kim ◽

Jae Hui Kim

Keyword(s):

Visual Acuity ◽

Retrospective Study ◽

Macular Degeneration ◽

Treatment Response ◽

Visual Outcome ◽

Age Related Macular Degeneration ◽

Neovascular Amd ◽

Age Related ◽

The Mean

Purpose: To investigate the limited response to aflibercept after switching to aflibercept in neovascular age-related macular degeneration (AMD). Methods: This retrospective study included 70 eyes with neovascular AMD that were initially treated with ranibizumab and then switched to aflibercept. The incidence and timing of the limited response to aflibercept were identified and visual outcome was compared between eyes with and without limited response. In addition, factors predictive of limited response were analyzed. Results: A limited response to aflibercept was noted in approximately 1/5 of the patients who underwent switching to aflibercept in neovascular AMD. Switching to aflibercept was performed at a mean of 16.2 ± 12.7 months after diagnosis. During the mean 34.7 months of follow-up after switching, limited response was noted in 15 eyes (21.4%) at a mean of 22.0 ± 13.9 months after switching. The degree of reduction in visual acuity was mean logMAR 0.34 ± 0.41 in eyes with limited response and mean 0.06 ± 0.20 in eyes without (p = 0.002). In addition, the duration between the diagnosis and the switching was shorter (p = 0.012), and the number of ranibizumab injections before switching was lower (p = 0.016) in eyes with limited response than in eyes without. Conclusions: Patients who showed limited response to aflibercept after switching to aflibercept showed a worse visual outcome. The probability of having a limited response is higher when the switching is performed earlier.

Download Full-text

The Presence of Intra- or Subretinal Fluid during the Loading Phase in the Treatment of Exudative Age-Related Macular Degeneration with Intravitreal Ranibizumab Assessed by Optical Coherence Tomography

Ophthalmologica ◽

10.1159/000430103 ◽

2015 ◽

Vol 234 (2) ◽

pp. 61-66

Author(s):

Andreas Ebneter ◽

Boris Gekkiev ◽

Bhuvan Chanana ◽

Sebastian Wolf ◽

Martin S. Zinkernagel

Keyword(s):

Optical Coherence Tomography ◽

Visual Acuity ◽

Macular Degeneration ◽

Subretinal Fluid ◽

Age Related Macular Degeneration ◽

Optical Coherence ◽

Intravitreal Ranibizumab ◽

Visual Improvement ◽

Age Related ◽

Treatment Naïve

Purpose: To assess intra- and subretinal fluid during the loading phase with intravitreal ranibizumab in exudative age-related macular degeneration and to quantify the accuracy of crosshair scan spectral-domain optical coherence tomography with regard to retinal fluid. Methods: This is a retrospective study of 31 treatment-naive patients who received 3 monthly intravitreal ranibizumab injections. Visual acuity and the presence of retinal fluid were assessed at each visit using volume and crosshair scan protocols. Results: Visual acuity improved and central retinal thickness decreased significantly during the loading phase. However, retinal fluid persisted in two thirds of the patients. The accuracy of the crosshair scan to detect fluid was 93%. Conclusions: A substantial proportion of eyes had persistent fluid after 3 months of ranibizumab injections. However, visual improvement was independent of residual fluid. Message: Crosshair scans detect relevant collections of retinal fluid accurately and may be sufficient in daily clinical practice.

Download Full-text

Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome

Graefe s Archive for Clinical and Experimental Ophthalmology ◽

10.1007/s00417-014-2789-x ◽

2014 ◽

Vol 253 (8) ◽

pp. 1211-1216 ◽

Cited By ~ 10

Author(s):

Liuna Jang ◽

Christina Gianniou ◽

Aude Ambresin ◽

Irmela Mantel

Keyword(s):

Visual Acuity ◽

Macular Degeneration ◽

Subretinal Fluid ◽

Age Related Macular Degeneration ◽

Intravitreal Ranibizumab ◽

Age Related

Download Full-text

Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

BMC Ophthalmology ◽

10.1186/s12886-021-01816-7 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Yuji Oshima ◽

Yumi Ishibashi ◽

Naoyasu Umeda ◽

Tatsuo Nagata ◽

Shigeo Yoshida ◽

...

Keyword(s):

Visual Acuity ◽

Visual Function ◽

Age Related Macular Degeneration ◽

Open Label ◽

Intravitreal Ranibizumab ◽

Satisfaction Questionnaire ◽

Age Related ◽

The Mean ◽

Baseline Visual Acuity ◽

Ranibizumab Treatment

Abstract Background To evaluate the correlation between visual acuity improvement and vision-related QOL after ranibizumab treatment in Japanese patients with AMD. Methods In this one-year prospective, interventional, open-label, multicenter study involving four sites, patients with neovascular AMD were enrolled and observed for 12 months. Treatment-naïve patients received 0.5 mg ranibizumab as needed after three initial monthly doses. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at every visit. Evaluations with the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and patient satisfaction questionnaire were performed at baseline and 3 and 12 months after initial treatment. The primary endpoint was change in BCVA and QOL 3 months after ranibizumab treatment. QOL outcomes were also assessed in the better and poor BVCA subgroups. Results The study enrolled 100 patients. The mean logMAR BCVA after treatment improved significantly from 0.43 to 0.30 at 3 months (p< 0.0001), and 0.28 at 12 months (p< 0.0001). The mean NEI-VFQ-25 composite scores improved from 79.48 to 84.13 at 3 months (p< 0.0001), and 86.0 at 12 months (p< 0.0001). The 3 and 12-month changes in NEI-VFQ-25 score and BCVA showed significant correlation. In the poor baseline visual acuity group (decimal BCVA ≤0.5), there was a significant correlation between the changes in the NEI-VFQ-25 score and BCVA (p=0.02) but not in the better baseline visual acuity group (decimal BCVA > 0.6, p=0.1) at 3 months. There were no significant differences in the satisfaction questionnaire score from baseline to at 3 months (p=0.54) and 12 months (p=0.23). The average CMT improved significantly from 340 to 264 μm at 3 months (p< 0.0001) and to 268 μm at 12 months (p< 0.0001). Conclusions Intravitreal ranibizumab treatment resulted in improvement in visual acuity, anatomical change, and visual function change in Japanese AMD patients. Significant improvement was seen in patient visual function, and this was correlated with changes in VA, except immediately after loading dose treatment in patients with higher baseline VA. The patients’ satisfaction with the treatment remained unchanged during the study period. Trial registration This study is registered at UMIN Clinical Trials Registry (UMIN000012013). Registered October 10, 2013, as prospective study.

Download Full-text